<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088724</url>
  </required_header>
  <id_info>
    <org_study_id>OORRPED 1</org_study_id>
    <nct_id>NCT01088724</nct_id>
  </id_info>
  <brief_title>Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)</brief_title>
  <acronym>FCD-R</acronym>
  <official_title>Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fludarabine may be of benefit to prevent rejection of grafted solid organs in children during
      chemo-immunotherapy treatment for post transplant lymphoproliferative diseases (PTLDs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible to this study were patients less than 18 years old, presenting with non Burkitt,
      aggressive, CD20 positive PTLD, after solid organ transplants.

      Induction therapy consisted of two cycles of a combination of Fludarabine(30mg/sqm/day, days
      1,2,3), Cyclophosphamide (750 mg/sqm/day, day 1), Doxorubicin (30 mg/sqm/day, day 1)and
      Rituximab (375 mg/sqm/day, day 4).

      Thereafter consolidation therapy was given as follows: two blocks for stage II or III with
      LDH less than 500 IU/L; three blocks for stage III with LDH &gt;500 and &lt; 1000 IU/L or stage IV
      with LDH &lt; 1000 IU/L; four blocks for stage III or IV with LDH &gt; 1000 IU/L. Blocks given were
      modified BFM blocks used for treatment of non Hodgkin B-lymphomas, as follows:

      Block 1: High Dose Methotrexate (HDMTX) 1.5 gr/sqm; Vincristine (VCR,1.5 mg/sqm); Cytarabine
      (from 120 to 150 mg/sqm x4); Ifosfamide (600 mg/sqm/day x5); VP-16 (80 mg/sqm/day x2);
      Dexamethasone (DXM,10 mg/sqm/day for 5 ays); Intrathecal
      Methotrexate-Cytarabine-Methylprednisolone(TIT).

      Block 2:HDMTX (3 gr/sqm); VCR (1.5 mg/sqm); Daunomycin (20 mg/sqm/day x2); Cyclophosphamide
      (160 mg/sqm/day x5); DXM (10 mg/sqm/day x5); TIT

      Block 3:Vindesine (3 mg/sqm); Cytarabine (3000 mg/sqm q 12 hours x4); VP-16 (100 mg/sqm q 12
      hours x4); DXM (20 mg/sqm/day x5);

      Block 4 as Block 1.

      Outcome measures are: achievement of complete remission after induction therapy; incidence of
      infectious episodes; neurological toxicity; incidence of graft rejection; duration of
      complete remission.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>6 months</time_frame>
    <description>No evidence of disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>graft rejection rate</measure>
    <time_frame>1 year after treatment</time_frame>
    <description>preservation of normal organ function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous complete remission rate</measure>
    <time_frame>five years after the diagnosis</time_frame>
    <description>No evidence of disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Post-transplant Lymphoproliferative Disease (PTLD)</condition>
  <condition>Non Burkitt</condition>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine, cyclophosphamide, doxorubicin, rituximab</intervention_name>
    <description>Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).</description>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children less 18 years old and

          -  Non Burkitt, CD20 positive aggressive PTLD and

          -  Solid organ transplant

        Exclusion Criteria:

          -  Burkitt PTLD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentino Conter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatrics, Ospedali Riuniti di Bergamo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>March 16, 2010</last_update_submitted>
  <last_update_submitted_qc>March 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Eugenia Giraldi</name_title>
    <organization>Ospedali Riuniti di Bergamo, Italy</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

